Nutritional composition and application thereof

Abstract

The invention provides a nutritional composition and application of the nutritional composition. The nutritional composition comprises medium-chain and long-chain fatty acid triglyceride and a milk fat globule membrane in a mass ratio of (2: 1)-(97: 1), and the medium-chain and long-chain fatty acid triglyceride and the milk fat globule membrane have a synergistic effect in the aspects of promoting skeletal development, especially increasing bone mineral density and / or preventing or treating osteogenesis insufficiency and / or osteoporosis.

Description

Technical Field

[0001] The present disclosure relates to the technical field of food or medicine, and in particular to a nutritional composition for improving bone development, especially increasing bone density and / or preventing or treating osteogenesis imperfecta and / or osteoporosis, a food and a medicine containing the nutritional composition, and an application of the nutritional composition. Background Art

[0002] Bone formation is affected by many factors, including genetics, nutrition, health, and the environment. Bone formation begins with embryonic development. During childhood and adolescence, bone mass increases with age until the bones mature and reach peak bone mass in adolescence. The increase in peak bone mass reduces the risk of osteoporosis in later life. A 10% increase in maximum bone mass during growth will reduce the risk of osteoporotic fractures by 50%. Therefore, improving bone growth through breast milk and dietary nutrition in the early stages of life, especially in infancy, childhood, and adolescence, may play a huge role in bone health later in life. Increasing peak bone mass during growth is of great significance for maintaining adolescent bone health (Liu Gan et al., Food Science and Technology, 2023; 48(03): 253-259).

[0003] Breast milk contains a variety of nutrients and immune factors, so it is the best choice for infant nutrition. Breastfeeding is the diet recommended by the World Health Organization for the first 6 months after birth. Studies have shown that breast milk has many beneficial effects on infant growth and development, disease prevention, etc. (HAROON S et al., BMC Public Health, 2013; 13 (Suppl3): S20). Among them, medium and long-chain triacylglycerols (MLCT) in breast milk have attracted widespread attention as a star product among new structural lipids. The fatty acid composition of MLCT is closer to breast milk, which is conducive to fat digestion and absorption, improves the absorption of lipid nutrients, inhibits the accumulation of body fat, and can quickly and stably supply energy (Cheng X et al., Annu Rev Food Sci Technol. 2024; 15 (1): 381-408). In addition, the main structural feature of MLCT is that medium-chain fatty acids and long-chain fatty acids are simultaneously connected to the same glycerol backbone. Early studies have shown that MLCT has many health functions, such as lowering blood lipids, inhibiting obesity, reducing diabetes and cardiovascular diseases, and reducing the risk of cancer (Lai Yundong et al., Chinese Journal of Oil Crops, 2024; 46(04): 719-727).

[0004] Chinese patent CN118556870B discloses a nutritional composition comprising medium-chain fatty acid triglycerides and casein phosphopeptides in a mass ratio of 8:1-25:1. The nutritional composition can be used to improve brain or cognitive development.

[0005] Chinese patent CN118592494B discloses the use of a fat composition in improving the temperament of infants or children, wherein the mass ratio of the UPU structured fat composition to the medium-chain fatty acid edible oil is 1:1-1.5:1.

[0006] In addition, milk fat globule membrane (MFGM) is a complex three-layer phospholipid protein membrane composed of polar lipids, cholesterol and proteins wrapped on the surface of milk fat droplets. Its safety and tolerability have been confirmed in clinical trials. Early studies have shown that adding "whey protein powder rich in milk fat globule membrane" to infant formula can promote the cognitive development of infant brain and improve infant immunity (Chinese Society of Food Science and Technology, Scientific Consensus on Milk Fat Globule Membrane and Its Ingredients, Journal of Chinese Institute of Food Science and Technology, 2022;22(04):471-476).

[0007] Chinese patent CN114128757B discloses the use of milk fat globule membrane in reducing the odor of dairy products, wherein the dairy products are solid dairy products or liquid dairy products; the solid dairy products are selected from infant formula milk powder, children's formula milk powder or middle-aged and elderly formula milk powder.

[0008] However, there are no reports at home or abroad on the effects of long-chain fatty acid triglycerides and milk fat globule membrane on bone development.

[0009] There is still a need in the art for methods that can promote bone development and increase bone density. Summary of the invention

[0010] The present invention has been made in view of the above-mentioned problems in the art.

[0011] A first aspect of the present invention provides a nutritional composition, comprising medium-chain fatty acid triglycerides and milk fat globule membrane, wherein the mass ratio of the medium-chain fatty acid triglycerides to the milk fat globule membrane is 2:1-97:1.

[0012] The second aspect of the present invention provides a food comprising the nutritional composition according to the first aspect of the present invention.

[0013] The third aspect of the present invention provides a medicine comprising the nutritional composition according to the first aspect of the present invention.

[0014] The fourth aspect of the present invention provides use of the nutritional composition described in the first aspect of the present invention in preparing food for promoting bone development.

[0015] The fifth aspect of the present invention provides use of the nutritional composition described in the first aspect of the present invention in preparing food for increasing bone density.

[0016] The sixth aspect of the present invention provides use of the nutritional composition described in the first aspect of the present invention in the preparation of a medicament for preventing or treating osteoporosis and / or osteogenesis imperfecta.

[0017] The seventh aspect of the present invention provides use of the nutritional composition according to the first aspect of the present invention for the non-therapeutic purpose of promoting bone development.

[0018] The eighth aspect of the present invention provides use of the nutritional composition according to the first aspect of the present invention for the non-therapeutic purpose of increasing bone density.

[0019] The present invention finds that when medium-chain fatty acid triglycerides and milk fat globule membrane are used in combination at a defined mass ratio, there is a synergistic effect between the two, which can synergistically improve bone development, especially increase bone density and / or prevent or treat osteogenesis imperfecta and / or osteoporosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 Typical graphs showing the fluorescence intensity of zebrafish osteogenesis after treatment with the normal control group, positive control group, and samples of formulas 1-6.

[0021] Figure 2 A typical graph showing the fluorescence intensity of zebrafish osteogenesis after treatment with samples of Comparative Examples 1-6 and Formulation 7. DETAILED DESCRIPTION

[0022] The following definitions are provided to facilitate understanding of the present invention by those skilled in the art. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those of ordinary skill in the art to which the present invention belongs. Preferred materials and methods are described herein, but any methods and materials similar to or equivalent to those described herein may be used in the practice of the present invention's tests. It should also be understood that the terms used herein are only for the purpose of describing specific embodiments and are not intended to be limiting.

[0023] Definition of terms

[0024] Unless otherwise indicated or defined, all terms used have the usual meaning in the art, which will be understood by those skilled in the art. In addition, unless otherwise specified, all methods, steps, techniques and operations not specifically described in detail can and have been performed in a manner known per se, which will be understood by those skilled in the art.

[0025] As used herein, the term "medium-chain triglyceride" or "MLCT" is a special triglyceride in which medium-chain fatty acids and long-chain fatty acids coexist on the triglyceride backbone. MLCT is made from edible vegetable oil and medium-chain triglycerides (derived from edible coconut oil and palm kernel oil) by lipase transesterification, distillation separation, decolorization, deodorization and other processes. Medium-chain triglycerides can be derived from medium-chain edible fatty acid edible oil.

[0026] As used herein, the term "medium-chain fatty acid" refers to a fatty acid having 6-12 carbon atoms in the carbon chain, such as caproic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc.; the term "long-chain fatty acid" refers to a fatty acid having more than 14 carbon atoms, generally 14-30 carbon atoms, in the carbon chain, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid, etc. The terms "medium-chain fatty acid triglyceride" and "long-chain fatty acid triglyceride" refer to the esterification reaction products of "medium-chain fatty acid" and "long-chain fatty acid" with glycerol, respectively; the term "medium-long chain fatty acid triglyceride" refers to triglycerides containing both medium-chain fatty acid residues and long-chain fatty acid residues in the molecular structure. The present invention has no special requirements for the medium-long chain fatty acid triglyceride used, and the medium-long chain fatty acid triglyceride commonly used in the art can be used. The medium-chain fatty acid triglycerides can be used in pure form or in an impure form rich in medium-chain fatty acid triglycerides. For example, the medium-chain fatty acid triglycerides used in the present invention can contain C6-C 12 Fatty acid residues and C 14 -C 30 Fatty acid residue. C6-C 12 The fatty acid residue may be derived from one or more of the following: hexanoic acid, heptanoic acid, octanoic acid, nonanoic acid, decanoic acid, undecanoic acid, dodecanoic acid, etc. 14 -C 30 The fatty acid residue may be derived from one or more of the following: myristic acid, palmitic acid, heptadecanoic acid, oleic acid, linoleic acid, stearic acid, nonadecanoic acid, eicosapentaenoic acid, heneicosanoic acid, docosatetraenoic acid, docosahexaenoic acid, tricosanoic acid, tetracosenoic acid, eicosapentaenoic acid, hexacosahexenoic acid, arachidonic acid, etc. In some embodiments, the C6-C 12 The fatty acid residue is derived from one or more of the following: caproic acid, caprylic acid, capric acid and lauric acid; and / or the C 14 -C 30 The fatty acid residue is derived from one or more of the following: myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid.12 The fatty acid residues on the C 14 -C 30 The weight ratio of fatty acid residues is 0.124 to 2.000. In some embodiments, C6-C 12 The fatty acid residues on the C 14 -C 30 The weight ratio of fatty acid residues can be 0.124, 0.125, 0.130, 0.140, 0.150, 0.160, 0.170, 0.180, 0.190, 0.200, 0.300, 0.400, 0.500, 0.600, 0.700, 0.800, 0.900, 1.000, 1.100, 1.200, 1.300, 1.400, 1.500, 1.600, 1.700, 1.800, 1.900, 2.000 or any two thereof. In some embodiments, the "medium and long chain fatty acid triglyceride" can be prepared with reference to the method of patent CN115369132A.

[0027] As used herein, the term "milk fat globule membrane" or "MFGM" (Milk Fat Globule Membrane in English) is a complex biological membrane structure present in breast milk. The milk fat globule membrane is a complex three-layer phospholipid protein membrane wrapped on the surface of milk fat droplets, composed of polar lipids, cholesterol and proteins, while sphingomyelin and gangliosides are characteristic indicators of the milk fat globule membrane ingredients, and their safety and tolerability have been confirmed in clinical trials. In principle, there is no particular restriction on the source of the milk fat globule membrane of the present invention. It can usually be obtained by extraction from animal milk or its products. In some preferred embodiments, such animal milk or its products can be cow's milk, goat's milk, camel's milk, horse's milk or dairy products based on them (such as cheese), etc. More preferably, it can be extracted from cow's milk, including bovine colostrum or bovine milk. The present invention does not particularly limit the preparation process of MFGM. For example, it can be carried out using an acidified acid precipitation-centrifugation-isoelectric point enrichment-drying method, or MFGM can be separated using an existing membrane filtration method. In addition, MFGM can also be obtained through commercially available products, including milk fat globule membrane whey protein powder and milk fat globule membrane milk protein powder. Milk fat globule membrane whey protein powder refers to a powdered product containing milk fat globule membrane made from raw milk or whey through separation, concentration, drying and other processes. Milk fat globule membrane milk protein powder refers to a powdered product containing milk fat globule membrane made from raw milk or cream through separation, concentration, drying and other processes. Commercial sources of MFGM in the present invention include Lacprodan® MFGM-10, Lacprodan® PL-20, Cor-Powe® SM2, lipid-rich MFGM fraction or buttermilk powder concentrate BPC50, BPC60, G600, PC700, Hilmar Cor-Power® or WPC7500MEGM ENRICHED WPC, etc.

[0028] As used herein, "osteoblasts" are the main functional cells of bone formation, playing a key role in the growth and development of bones, bone remodeling and the repair process after fracture. When osteoblasts are activated, they undergo processes such as cell proliferation, extracellular matrix maturation, mineralization, etc., to form new bones. Osteoblasts play a key role in bone development. The dysfunction of osteoblasts is closely related to skeletal dysplasia. In this article, skeletal dysplasia can be any type of skeletal dysplasia, including but not limited to skeletal dysplasia caused by osteoblast dysfunction, such as osteogenesis imperfecta and osteoporosis.

[0029] As used herein, "bone density" refers to the amount of bone contained per unit volume (volume density) or per unit area (area density). Osteoblasts are the main functional cells for bone formation and play a vital role in the maintenance and increase of bone density.

[0030] As used herein, "osteoporosis" is a systemic bone disease characterized by decreased bone mass and destruction of bone microstructure, which leads to increased bone fragility and susceptibility to fractures. Decreased osteoblast activity leads to decreased bone formation, while relatively enhanced osteoclast activity leads to increased bone resorption, ultimately causing decreased bone mass and osteoporosis.

[0031] As used herein, "fracture healing disorder" refers to abnormal conditions that occur during the normal healing process of a fracture, resulting in prolonged fracture healing or complete failure of fracture healing. Osteoblasts are responsible for the synthesis and mineralization of bone matrix during fracture healing, and impaired osteoblast function will delay fracture healing.

[0032] Nutritional composition

[0033] A first aspect of the present invention provides a nutritional composition, comprising medium-chain triglycerides (MLCT) and milk fat globule membrane (MFGM), wherein the mass ratio of the medium-chain triglycerides to the milk fat globule membrane is 2:1-97:1.

[0034] The present invention finds that when medium-chain fatty acid triglycerides and milk fat globule membrane are used in combination at a defined mass ratio, there is a synergistic effect between the two, which can synergistically improve bone development, especially increase bone density and / or prevent or treat osteogenesis imperfecta and / or osteoporosis.

[0035] In some embodiments, the nutritional composition consists of medium-chain triglycerides (MLCT) and milk fat globule membrane (MFGM).

[0036] In an embodiment, the mass ratio of the medium and long chain fatty acid triglycerides to the milk fat globule membrane in the nutritional composition is 2:1 to 97:1, for example, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 97:1 or within the range defined by any two of them.

[0037] In some embodiments, the mass ratio of the medium and long chain fatty acid triglycerides to milk fat globule membrane in the nutritional composition is 2.67:1 to -96.03:1, for example, 10.67:1, 2.67:1, 32.01:1, 8.01:1, 2.00:1, or 96.03:1.

[0038] food

[0039] The second aspect of the present invention relates to a food, which comprises the nutritional composition according to the first aspect of the present invention.

[0040] All the above descriptions about the first aspect of the present invention are applicable here and will not be repeated here.

[0041] In some embodiments, the food may be, for example, a functional food, a health food, or a health product.

[0042] In some embodiments, the food is a common food or a special food. As an example, the food can be selected from dairy products, candies, beverages, bread and biscuits, for example, the food can be selected from milk powder or fermented food. In some embodiments, the milk powder is infant formula milk powder.

[0043] In some embodiments, the food is an infant food such as an infant formula.

[0044] In some embodiments, the food product may be in the form of a powder, a tablet, or a liquid.

[0045] In some embodiments, based on the dry weight of the food, the content of medium and long chain fatty acid triglycerides can be 0.1% to 30.0%, preferably 0.4% to 30.0%. As an example, based on the weight of the product, the content of medium and long chain fatty acid triglycerides can be 0.1, 0.2, 0.5, 0.8, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, 28.0, 29.0, 30.0 dry basis weight%, or any two of them in the range defined. The content of milk fat globule membrane can be calculated based on the ratio of the two.

[0046] In some embodiments, based on the dry weight of the food, the content of milk fat globule membrane can be 0.001% to 15.0%. As an example, based on the weight of the product, the content of milk fat globule membrane can be 0.001, 0.005, 0.01, 0.05, 0.1, 0.2, 0.5, 0.8, 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 12.0, 13.0, 14.0, 15.0 dry weight%, or within the range defined by any two of them.

[0047] In addition, it is easy for those skilled in the art to understand that, in addition to the nutritional composition of the first aspect of the present invention, the food also includes one or more selected from the following: raw milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blending oil, oligofructose, oligogalactose, nucleotides, choline, vitamins, minerals, DHA and taurine.

[0048] For example, when the food is milk powder, in addition to the nutritional composition described in the first aspect of the present invention, the milk powder may also include proteins such as α-lactalbumin and milk fat globule membrane protein; carbohydrates such as lactose; lipids; minerals such as calcium, iron, phosphorus, etc.; vitamins; other additives such as whey powder, choline bitartrate, docosahexaenoic acid, arachidonic acid, walnut oil, etc.

[0049] The food can be produced by a preparation method commonly used in the art, which will not be described in detail here.

[0050] drug

[0051] The third aspect of the present invention relates to a medicine comprising the nutritional composition according to the first aspect of the present invention.

[0052] All the above descriptions about the first aspect of the present invention are applicable here and will not be repeated here.

[0053] The dosage form of the drug is not limited, and may be, for example, one or more of tablets, granular powders, capsules, and liquids.

[0054] When the medicament comprises the nutritional composition, the medicament can be used for preventing or treating osteogenesis imperfecta and / or osteoporosis.

[0055] application

[0056] The fourth aspect of the present invention relates to the use of the nutritional composition of the first aspect of the present invention in the preparation of food (such as health food) for promoting bone development.

[0057] The promotion of bone development may include, for example, promoting the formation, growth, remodeling and accumulation of bone mass.

[0058] The fifth aspect of the present invention relates to the use of the nutritional composition of the first aspect of the present invention in the preparation of food for increasing bone density (eg, health food).

[0059] The sixth aspect of the present invention relates to use of the nutritional composition of the first aspect of the present invention in the preparation of a medicament for preventing or treating osteogenesis imperfecta and / or osteoporosis.

[0060] The seventh aspect of the present invention relates to the use of the nutritional composition of the first aspect of the present invention for the non-therapeutic purpose of promoting bone development.

[0061] The eighth aspect of the present invention relates to the use of the nutritional composition of the first aspect of the present invention for the non-therapeutic purpose of increasing bone density.

[0062] For the nutritional composition, all the above descriptions about the first aspect of the present invention are applicable here and will not be repeated here.

[0063] For the food, the above description about the second aspect of the present invention is applicable here and will not be repeated here.

[0064] Regarding the drug, in some embodiments, its dosage form includes but is not limited to tablets, granular powders, capsules and liquids.

[0065] All the above descriptions about the first aspect of the present invention are applicable here and will not be repeated here. In some embodiments, when the composition, food or medicine is orally administered to a human body, the dosage of medium and long chain fatty acid triglycerides is 0.1 to 30 g / day, preferably 0.4 to 30 g / day, for example, 0.1 g / day, 0.2 g / day, 0.3 g / day, 0.4 g / day, 0.5 g / day, 0.6 g / day, 0.7 g / day, 0.8 g / day, 0.9 g / day, 1 g / day, 2 g / day, 3 g / day, 4 g / day, 5 g / day, 6 g / day, 7 g / day, 8 g / day, 9 g / day, 10 g / day, 11 g / day, 12 g / day, 13 g / day, 14 g / day, 15 g / day, 16 g / day, 17 g / day, 18 g / day, 19 g / day, 20 g / day, 21 g / day, 22 g / day, 23 g / day, 24 g / day, 25 g / day, 26 g / day, 27 g / day, 28 g / day, 29 g / day, or 30 g / day, or a range defined by any two of them. The dosage of the milk fat globule membrane can be converted according to the ratio with medium and long chain fatty acid triglycerides.

[0066] In some embodiments, when the composition, food or medicine is orally administered to humans, the dosage of milk fat globule membrane is 0.001 g / day-15 g / day, for example, 0.001 g / day, 0.002 g / day, 0.003 g / day, 0.004 g / day, 0.005 g / day, 0.006 g / day, 0.007 g / day, 0.008 g / day, 0.009 g / day, 0.01 g / day, 0.02 g / day, 0.03 g / day, 0.04 g / day, 0.05 g / day, 0.06 g / day, 0.07 g / day, 0.08 g / day, 0.09 g / day, 0.1 g / day, 0.2 g / day, 0.3 g / day, 0.4 g / day, 0.5 g / day, 0.6 g / day, 0.7 g / day, 0.8 g / day, 0.9 g / day, 0.1 g / day, 0.2 g / day, 0.3 g / day, 0.4 g / day, 0.5 g / day, 0.6 g / day, 0.7 g / day, 0.8 g / day, 0.9 g / day, 1 g / day, 2 g / day, 3 g / day, 4 g / day, 5 g / day, 6 g / day, 7 g / day, 8 g / day, 9 g / day, 10 g / day, 11 g / day, 12 g / day, 13 g / day, 14 g / day, 15 g / day or any range therebetween. Medium-chain triglycerides and milk fat globule membranes can be formulated into compositions or preparations for easy administration by subjects. Alternatively, medium-chain triglycerides and milk fat globule membranes can be taken separately without being formulated into the same composition, for example, taken simultaneously or taken separately. In the case of separate administration, medium-chain triglycerides and milk fat globule membranes can be taken at intervals of a certain time within a day. Long-chain triglycerides and milk fat globule membranes can also be taken several times a day. The time interval between the administration of the two components or the number of separate administrations is easily determined by a person skilled in the art.

[0067] Example

[0068] The present invention will be more easily understood with reference to the following examples, which are merely provided to illustrate certain aspects and embodiments of the present invention and are not intended to limit the present invention.

[0069] Unless otherwise stated, the reagents used in this embodiment are all commercially available materials or conventional materials. The medium-chain fatty acid triglycerides (MLCT) in all the following embodiments are derived from medium-chain fatty acid edible oil (purity of 69 ± 10%), produced by Qingdao Haizhiyuan Life Science Technology Co., Ltd., with a production batch number of Y1505-22120101; milk fat globule membrane (MFGM), purchased from Arla, product name Lacprodan® MFGM-10, batch number P510216, the phospholipid content in the raw material is 8 ± 2%, the protein content is 71.5 ± 5% by weight, and the sphingomyelin g / 100g phospholipids is 25 ± 10g.

[0070] Vancomycin was obtained from Shanghai MacLean Biochemical Technology Co., Ltd., white powder, batch number C12976208.

[0071] AB strain zebrafish: provided by the fish breeding center of Hangzhou Huante Biotechnology Co., Ltd.

[0072] Example 1 Determination of Maximum Tolerated Concentration (MTC) of a Single Sample

[0073] Wild-type AB zebrafish 3 days post-fertilization (3 dpf) were randomly selected and placed in beakers. Each beaker (experimental group) was treated with 30 zebrafish. Water-soluble samples (concentrations shown in Table 1) were administered, and a normal control group was set up at the same time. The capacity of each beaker was 20 mL. The solution was changed once at 5 dpf. After treatment at 28°C for 3 days, the MTC of the samples on normal zebrafish was measured.

[0074] Table 1. Results of the single sample concentration experiment to explore the effect of promoting bone development (n = 30)

[0075]

[0076] As shown in Table 1, the MTC of medium-chain fatty acid triglycerides is 750 μg / mL, and the MTC of milk fat globule membrane MFGM is 125 μg / mL. The subsequent drug administration experiment design was carried out with reference to the above MTC.

[0077] Example 2 Samples to promote bone development efficacy evaluation experiment

[0078] The fluorescence intensity of osteoblasts is closely related to bone development and disease. Studies have shown that changes in the fluorescence intensity of osteoblasts can reflect their biological functions and states. For example, the structure of the cytoskeleton microfilaments of osteoblast-like cells changes after being subjected to force, and the fluorescence intensity decreases accordingly, but the fluorescence intensity gradually recovers and increases after the stimulus is removed, indicating that changes in the cytoskeleton are recoverable and remodelable. In addition, changes in fluorescence intensity are also related to the differentiation and activity of osteoblasts, such as the increase in the fluorescence intensity of osteoblast cytoskeleton proteins after static magnetic field treatment. These changes may be related to bone development, repair and disease states (such as osteoporosis). The fluorescence intensity of osteoblasts is an important indicator for studying bone health and disease.

[0079] 3 dpf transgenic teleost green fluorescent zebrafish were randomly selected and placed in beakers, and 30 zebrafish were treated in each beaker (experimental group). The samples were dissolved in water (concentrations are shown in Table 2), the positive control Swisse "Calcium & Vitamin D" was 500μg / mL, and a normal control group was set up at the same time. The capacity of each beaker was 20 mL. The medium was changed once at 5 dpf. After 3 days of treatment at 28℃, 10 zebrafish were randomly selected from each experimental group and photographed under a fluorescence microscope. NIS-ElementsD3.20 advanced image processing software was used to analyze and collect data, and the fluorescence intensity of zebrafish osteogenesis was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of the samples in promoting bone development. The statistical analysis results were expressed as mean ± SE. SPSS26.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.

[0080] According to the above method, medium-chain fatty acid triglycerides, MFGM single samples and combinations of different ratios and doses were administered to zebrafish, and the dosages were shown in Table 2. The administration results are shown in Tables 2 and Figure 1-Figure 2 shown.

[0081] Table 2 Results of the evaluation experiment on the efficacy of samples in improving bone development (osteogenesis fluorescence intensity)

[0082]

[0083] Note: Compared with the normal control group, *P<0.05, ***P<0.001.

[0084] From Table 2, Figure 1-Figure 2The results showed that compared with the normal control group, the osteogenic fluorescence intensity of the groups treated with MLCT (83.3 µg / mL, 250 µg / mL, 750 µg / mL) and MFGM (125 µg / mL) was significantly enhanced (P < 0.05), indicating that the single sample has the effect of improving bone development. In addition, compared with the normal control, the combination of MLCT and MFGM (formulations 1-7) can significantly improve bone development, specifically, the osteogenic fluorescence intensity is significantly enhanced (P < 0.05). In addition, according to Table 2, it can be seen that formulas 1-2 and 4-7 with a ratio of MLCT to MFGM of 2:1-96.03:1 have higher osteogenic fluorescence than formula 3 with a ratio of MLCT to MFGM of 0.67, indicating that they have better effects in improving bone development, especially increasing bone density and / or improving osteoporosis. In addition, it can be seen from Table 2 that in terms of composition, Formula 1 is equivalent to the combination of Comparative Example 1 and Comparative Example 4, and Formula 1, Comparative Example 1, and Comparative Example 4 increase the osteogenic fluorescence intensity by 521979 pixels, 346080 pixels, and 12893 pixels, respectively, relative to the normal control; the increment of osteogenic fluorescence intensity of Formula 1 (521979 pixels) is greater than the sum of the increments of Comparative Example 1 and Comparative Example 4 (358973 pixels), indicating that MLCT and MFGM in Formula 1 have a synergistic effect in improving bone development, especially increasing bone density and / or improving osteoporosis; similarly, for Formulas 2 and 4-7, it can also be concluded that MLCT and MFGM therein have a synergistic effect in improving bone development, especially increasing bone density and / or improving osteoporosis; that is, Formulas 1-2 and 4-7 with a ratio of MLCT to MFGM of 2.00-96.03 have a synergistic effect in improving bone development, especially increasing bone density and / or improving osteoporosis.

[0085] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent replacements for some of the technical features therein. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A nutritional composition, characterized in that The milk fat globule membrane comprises medium-chain fatty acid triglycerides and milk fat globule membrane, wherein the mass ratio of the medium-chain fatty acid triglycerides to the milk fat globule membrane is 2:1-97:

1.

2. Food, characterized in that The nutritional composition according to claim 1.

3. The food according to claim 2, characterized in that The food is selected from one or more of dairy products, candies, beverages, bread and biscuits.

4. The food according to claim 2, characterized in that The food is milk powder or fermented food.

5. The food according to claim 2, characterized in that The food is infant food.

6. The food according to claim 4, characterized in that The milk powder is infant formula milk powder.

7. Use of the nutritional composition according to claim 1 in preparing food, characterized in that: The food is used for promoting bone development.

8. Use of the nutritional composition according to claim 1 in preparing food, characterized in that: The food is used to increase bone density.

9. The use according to claim 7, characterized in that: The promotion of bone development includes the formation, growth, remodeling and accumulation of bone mass.

10. The use according to any one of claims 7 to 9, characterized in that: The food is a health food.

11. A drug, characterized in that The nutritional composition according to claim 1.

12. Use of the nutritional composition according to claim 1 in preparing medicines, characterized in that: The medicament is used for preventing or treating osteogenesis imperfecta and / or osteoporosis.

13. The use according to claim 12, characterized in that: The dosage form of the drug is one or more of tablets, granular powders, capsules and liquids.

14. Use of the nutritional composition according to claim 1 for the non-therapeutic purpose of promoting bone development.

15. Use of the nutritional composition according to claim 1 for the non-therapeutic purpose of increasing bone density.

Images